Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
How It Works 
News - Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI Summary - About
Anbio Biotechnology Class A Ordinary Shares(NNNN)
Advisory History & Simulated Performance *
*as per simulation (see disclosures)- ALL
- 1Y
- 1M
- 1W
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- PASS (Skip)
Stock price based on last close Advisory Performance History (Simulated)
Upturn Advisory & Investor View for NNNN
10/13/2026: NNNN (1-star) is currently NOT-A-BUY. Pass it for now.
Anbio Biotechnology is a specialized player in the point-of-care diagnostic market, focusing on immunoassay analyzers and consumable testing kits. The company’s primary strength lies in its integrated 'razor-and-blade' business model, which generates recurring revenue from testing reagents. Growth is driven by expanding its clinical diagnostics portfolio and improving manufacturing efficiency. However, investors must consider the significant competitive risks from large-cap incumbents and the inherent regulatory hurdles typical of the biotech industry. This stock is generally suited for growth-oriented investors who are comfortable with the volatility associated with medical technology companies and who will monitor the success of new product pipeline validations.
How to Read the Upturn Advisory
The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.
Company fundamentals, valuation, risks, and news provide supporting context about the business.
Investor Fit
| Investor style | Fit | Why |
|---|---|---|
| Growth investor | Strong fit | The company operates in a high-growth sector focusing on diagnostic innovation. |
| Momentum investor | Mixed fit | Trading performance is often linked to specific product approval news or health demand cycles. |
| Value investor | Weak fit | High R&D costs and early-stage scaling often result in premium valuations relative to current earnings. |
| Dividend investor | Weak fit | Capital is primarily allocated to growth and research rather than dividends. |
| Low-risk investor | Weak fit | Biotech stocks inherently carry higher volatility due to regulatory and clinical outcomes. |
Risk Profile
| Risk factor | Level | Why it matters |
|---|---|---|
| Price volatility | High | The stock can experience significant swings based on clinical trial results and regulatory updates. |
| Valuation risk | Medium / high | Growth expectations are often priced into the stock, leaving little margin for error. |
| Competition risk (diagnostics industry) | High | Anbio competes with well-funded incumbents that dominate distribution channels. |
| Business quality | Medium | The company has strong technical foundations but is still establishing a sustained market moat. |
| Dividend income | Low / none | Investors should not expect income generation from this asset. |
| Execution risk | Medium / high | Successfully scaling manufacturing while maintaining stringent quality control is a constant operational challenge. |
Price Behavior
Steep Decline
The stock price has dropped sharply with strong downward pressure.
Extreme Price Shocks
The stock has experienced exceptionally large and disruptive price movements during the period.
Analysis of Past Performance
Type Stock | Historic Profit 139.32% | Avg. Invested days 23 | Today’s Advisory PASS |
Upturn Advisory Rating  | Upturn Advisory Performance  2.0 | Stock Returns Performance  5.0 |
| Profits based on simulation | Last Close 10/13/2026 |
Upturn Scorecard
Upturn Star Rating 
Company Fundamentals
Financial Health Rating
Growth Momentum Score
Ownership
Top 5 Institutional Investors
Unit Economics (Per $1K Revenue)
Economic Dimensions
Quantitative Style Profile
Style Classification
Quality Focused
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 193.56M USD | Price to earnings Ratio 29.4 | 1Y Target Price - |
Price to earnings Ratio 29.4 | 1Y Target Price - | ||
Volume (30-day avg) 174.6K shares | Beta - | 52 Weeks Range 3.88 - 44.73 | Updated Date 10/13/2026 |
52 Weeks Range 3.88 - 44.73 | Updated Date 10/13/2026 | ||
Dividends yield (FY) - | Basic EPS (TTM) 0.15 |
How Company Makes Money
| Business area | What it includes | Retail investor read |
|---|---|---|
| Diagnostic Equipment | Sale and maintenance of Immunoassay and POCT analyzers. | Revenue comes from selling hardware used in hospitals and clinics. |
| Diagnostic Reagents | Recurring sales of consumable testing kits and laboratory reagents. | The company benefits from a 'razor-and-blade' model where machines drive ongoing sales of testing kits. |
| Geography | Global distribution with concentrated exposure in key emerging markets. | Sales are geographically diverse, offering exposure to international healthcare demand. |
Analyzing Revenue: Products, Geography and Growth
Revenue by Geography
Geography revenue - Year on Year
Valuation
Trailing PE 29.4 | Forward PE - | Enterprise Value 256.27M | Price to Sales(TTM) 22.39 |
Enterprise Value 256.27M | Price to Sales(TTM) 22.39 | ||
Enterprise Value to Revenue 29.64 | Enterprise Value to EBITDA 44.43 | Shares Outstanding 43.89M | Shares Floating 39.69M |
Shares Outstanding 43.89M | Shares Floating 39.69M | ||
Percent Insiders 4.78 | Percent Institutions 5.01 |
Financial Metrics
🧭 Investment Snapshot
Total Revenue (Scale)
Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.
Net Income (Profit)
Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.
Free Cash Flow (Cash Strength)
Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.
📈 Growth & Strength
Operating Income (Core Profit)
Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.
EBITDA (Cash Earnings)
Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.
Gross Profit (Unit Profitability)
Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.
🛡️ Financial Safety
Cash (Liquidity Buffer)
Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.
Total Debt (Leverage Risk)
Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.
Net Working Capital (Short-Term Health)
Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.
🧱 Balance Sheet Strength
Stockholder Equity (Net Worth)
Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.
Total Assets (Asset Base)
The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.
Income Before Tax (Pre-Tax Earnings)
Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.
⚙️ Cost & Drag Factors
Cost of Revenue (Production Cost)
Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.
Total Operating Expenses (Operating Cost)
Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.
Income Tax Expense (Tax Drag)
Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.
All company names, trademarks, logos, and brands are the property of their respective owners and are used for identification and informational purposes only. Use of these names, trademarks, and logos does not imply endorsement by their respective owners.